FOLAKE AJE: Open Payments
NPI 1952936114 · HIGHLAND, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$920 in 43 payments from 20 companies in 2025. Trend: 2023 $2,469 · 2024 $900 · 2025 $920
Food & beverage: $920
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 11 | $154 |
| Biogen, Inc. | 6 | $153 |
| TG Therapeutics, Inc. | 4 | $85 |
| Lilly USA, LLC | 3 | $69 |
| Genentech USA, Inc. | 3 | $65 |
| Eisai Inc. | 2 | $41 |
| Janssen Biotech, Inc. | 1 | $39 |
| Teva Pharmaceuticals USA, Inc. | 1 | $37 |
| Alexion Pharmaceuticals, Inc. | 1 | $32 |
| Neurocrine BioSciences, Inc. | 1 | $31 |
Products named: TYSABRI, KESIMPTA, BRIUMVI, AMYVID, Ocrevus Zunovo, Leqembi, AUSTEDO XR, ULTOMIRIS.
Industry payments across IN — which companies pay providers there.
